What the FDA labels say about taking them together
Mirabegron and solifenacin
Mirabegron's FDA label of December 24, 2025 names solifenacin in its drug interactions section; the solifenacin label PlainMeds reads does not name mirabegron. The mirabegron label: “In contrast, in adult OAB patients in clinical trials, MYRBETRIQ, taken as monotherapy or in combination with solifenacin succinate 5 mg, the mean increase in systolic and diastolic blood pressure at the maximum …”
Check it at the source: the mirabegron FDA label on DailyMed (effective December 24, 2025, Lupin Pharmaceuticals, Inc.); the solifenacin FDA label on DailyMed (effective February 4, 2026, Bostal LLC).
What does the mirabegron label say about solifenacin?
Mirabegron label, drug interactionsDrug interaction studies were conducted in adult patients to investigate the effect of coadministered drugs on the pharmacokinetics of mirabegron and the effect of mirabegron on the pharmacokinetics of coadministered drugs (e.g., ketoconazole, rifampin, solifenacin succinate, tamsulosin, and oral contraceptives) [see Clinical Pharmacology ( 12.3 )].
Myrbetriq label (Astellas Pharma US, Inc., August 1, 2024), drug interactionsWhen initiating a combination of mirabegron and digoxin with or without solifenacin succinate, use the lowest dose of digoxin; monitor serum digoxin concentrations to titrate digoxin dose to desired clinical effect.
Myrbetriq label (Astellas Pharma US, Inc., August 1, 2024), warnings and precautionsIn contrast, in adult OAB patients in clinical trials, MYRBETRIQ, taken as monotherapy or in combination with solifenacin succinate 5 mg, the mean increase in systolic and diastolic blood pressure at the maximum recommended mirabegron dose of 50 mg was approximately 0.5 to 1 mm Hg greater than placebo.
Source: FDA drug label (Myrbetriq, NDA202611), Astellas Pharma US, Inc., effective August 1, 2024 (SPL set ba9e9e15-e666-4c56-9271-2e24739cfa2d), via openFDA
Source: FDA drug label (MIRABEGRON), Lupin Pharmaceuticals, Inc., effective December 24, 2025 (SPL set d22d3d12-8466-46db-bc19-d13e87c6115c), via openFDA; the full label on DailyMed
What does the solifenacin label say about mirabegron?
Solifenacin's label (effective February 4, 2026) does not name mirabegron in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Solifenacin Succinate), Bostal LLC, effective February 4, 2026 (SPL set d155c739-6870-4938-ba91-8c1b4b90afe4), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Mirabegron | Solifenacin | |
|---|---|---|
| Labeled for | Overactive bladder | Overactive bladder |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $9.39 per tablet 50 mg tablet | $0.162 per tablet 10 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once